26 Results for "

B-cell surfaces

" in MedChemExpress (MCE) Product Catalog:
Products (26)

26 Results for "B-cell surfaces" in MCE Product Catalog:

  • Categories Recommended:
    More
3
3 Cited Publications
Cat. No.: HY-P99042
CAS No.: 2279068-37-8
Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9981
CAS No.: 1422527-84-1
Synonyms: XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208

Target:  

Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-NP006
CAS No.: 308083-69-4
Synonyms: SPA
Protein A (SPA) is an immunoglobulin (Ig)-binding protein that exists on the bacterial surface and can be freely secreted into the extracellular environment. Protein A blocks opsonophagocytosis and induces B cell apoptosis in vitro by binding to the Fc region of antibodies and the Fab region of B cell receptors. Protein A can form toxic immune complexes with IgG, thereby inducing leukocyte necrosis. Protein A contributes to the virulence expression of Staphylococcus aureus. Protein A triggers allergic reactions in IgG-pretreated mouse models. Protein A can be used in studies related to immune system diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99285
CAS No.: 1630074-14-4
Synonyms: hBU 12

Target:  

ADC Antibodies CD19

Research Areas:  

Cancer

Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .
loading...
    loading...
Cat. No.: HY-P99798
CAS No.: 2251756-52-0
Synonyms: AMG 420; BI-836909

Target:  

CD3

Research Areas:  

Cancer

Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
loading...
    loading...
Cat. No.: HY-P990785
CAS No.: 2490552-52-6
Synonyms: ABBV-383; TNB 383B

Target:  

CD3

Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-P99976

Target:  

CD19

Research Areas:  

Inflammation/Immunology

Anti-Mouse CD19 Antibody (1D3) is an IgG2a antibody inhibitor targeting mouse CD19. Anti-Mouse CD19 Antibody (1D3) reduces CD19 expression levels on the surface of B cells. Anti-Mouse CD19 Antibody (1D3) inhibits the replication of peritoneal B-1a cells .
loading...
    loading...
Cat. No.: HY-P990690
CAS No.: 2407760-40-9
Synonyms: MEDI-5752

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Cancer

Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 + T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 + B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .
loading...
    loading...
Cat. No.: HY-P991176
Synonyms: RO7443904

Target:  

CD19 CD28

Research Areas:  

Cancer

RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-157269
CAS No.: 1069110-72-0
Target:  

Hapten

Research Areas:  

Inflammation/Immunology

J10-1 is a hapten small molecule. J10-1 accelerates peptide exchange in MHC class II molecules in an HLA-DM-independent manner, and its effect is not affected by the polymorphism of the P1 pocket of MHC class II molecules. J10-1 enhances the processes of peptide dissociation, peptide binding and peptide association of MHC class II molecules on the surface of B cells. J10-1 can be used for research on immunoregulation .
loading...
    loading...
Cat. No.: HY-150749A
Purity:  99.82%
Target:  

IFNAR

Research Areas:  

Cancer

ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
loading...
    loading...
Cat. No.: HY-P991231

Target:  

CD19

Research Areas:  

Cancer

DI-B4 is an anti-CD19 monoclonal antibody that can bind to CD19 on the surface of B cells and has anti-tumor activity .
loading...
    loading...
Cat. No.: HY-148411
CAS No.: 167362-48-3
Synonyms: LJP 394 free base
Target:  

DNA/RNA Synthesis

Research Areas:  

Inflammation/Immunology

Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus .
loading...
    loading...
Cat. No.: HY-P5472
CAS No.: 129437-45-2
Research Areas:  

Others

Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)
loading...
    loading...
Cat. No.: HY-P2783
CAS No.: 79386-00-8
Target:  

HBV

Destruxin B2 (compound 5) is a natural depsipeptide that can be inhibits hepatitis B surface antigen (HBsAg) secretion in Hep3B cells with an IC50 1.30 μM .
loading...
    loading...
Cat. No.: HY-150749
CAS No.: 1198621-85-0
Target:  

IFNAR

Research Areas:  

Inflammation/Immunology Cancer

ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
loading...
    loading...
Cat. No.: HY-P99911
CAS No.: 1635395-27-5
Synonyms: MEDI-6383
Efizonerimod alfa (MEDI-6383) is a recombinant human OX40L IgG4P Fc fusion protein that assembles into a hexameric structure and exerts potent agonist activity upon binding to OX40. The activity of Efizonerimod alfa is enhanced by Fcγ receptor-mediated aggregation. Efizonerimod alfa binds to OX40 on the surface of activated T cells, induces NF-κB promoter activity in OX40-expressing T cells, and triggers the production of Th1-type cytokines, T cell proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. Efizonerimod alfa enhances the cytolytic activity of tumor-reactive T cells and slows tumor growth in immunodeficient mice. Efizonerimod alfa induces the proliferation of CD4, CD8, and B cells in the peripheral blood of healthy non-human primates. Efizonerimod alfa can be used in the research of advanced solid malignancies and melanoma .
loading...
    loading...
Cat. No.: HY-174737
Target:  

mRNA

Research Areas:  

Inflammation/Immunology

Human CD40LG mRNA encodes the human CD40 ligand (CD40LG) protein, a protein that is expressed on the surface of T cells. CD40LG regulates B cell function by engaging CD40 on the B cell surface.
loading...
    loading...
Cat. No.: HY-P992351

Target:  

Inhibitory Antibodies

Research Areas:  

Infection Cancer

ELB021 is an antibody inhibitor targeting the CD160 checkpoint. ELB021 specifically binds to CD160 on the cell surface and blocks its immune checkpoint pathway, thereby stimulating innate and adaptive anti-tumor immune responses. ELB021 effectively eliminates CD160-expressing cancer cells by enhancing T cell proliferation and CD8 + T cell-mediated cytotoxicity. Independent of PD-1 regulation, ELB021 is applicable to research related to B-cell leukemia and HIV-1 infection .
loading...
    loading...
Cat. No.: HY-P991903

Target:  

CD20

Research Areas:  

Cancer

PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20 .
loading...
    loading...